Stocks · News reference
Alpha Tau Medical Announces Completion Of Enrollment Of 48 Patients In Phase Pilot IMPACT Study Of Alpha DaRT With First-Line Chemotherapy In Unresectable Pancreatic Cancer; Targets Initial Data Early 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16
HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.14) by 257.14 percent. This is a 284.62 percent decrease over losses of $(0.13) per share